Autologous HBV-TCR T Cell Therapy (LioCyx-M) for the Treatment of Hepatocellular Carcinoma

Inclusion Criteria: * HCC diagnosis confirmed by histology/ cytology or clinically * HCC that is not amenable to curative surgical and/or locoregional therapies, or progressive disease after surgical and /or locoregional therapies * Has failed at least one line of systemic therapy for HCC * ECOG performance status ≤1 * Serum HBsAg positivity * Child-Pugh A (5 - 7 points) * Life expectancy of at least 1 year * HLA profile: HLA-A\*02:01 or HLA-A\*24:02 Exclusion Criteria: * Brain metastasis * Second primary malignancy that is clinically detectable at the time of consideration for study enrolment, except for in situ carcinoma of the cervix, non-melanoma skin carcinoma localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer and superficial bladder tumors * Concurrent administration of any other anti-tumour therapy, including cytotoxic chemotherapy, TKI therapy, and immunotherapy. * Use of any investigational product (IP) or investigational medical device within 28 days of study drug administration * Serum HBV DNA levels ≥ 200 IU/ml at screening * Serum HBsAg levels ≥ 10,000 IU/ml at screening * Women who are pregnant or breast-feeding